Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

1.

Hormone receptor-negative breast cancer: undertreatment of patients over 80.

Weiss A, Noorbaksh A, Tokin C, Chang D, Blair SL.

Ann Surg Oncol. 2013 Oct;20(10):3274-8. doi: 10.1245/s10434-013-3115-2. Epub 2013 Jul 10.

PMID:
23838924
[PubMed - indexed for MEDLINE]
2.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
[PubMed - indexed for MEDLINE]
3.

Triple-negative breast cancers: unique clinical presentations and outcomes.

Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW, McCullough AE, Pockaj BA.

Ann Surg Oncol. 2010 Oct;17 Suppl 3:384-90. doi: 10.1245/s10434-010-1260-4. Epub 2010 Sep 19.

PMID:
20853062
[PubMed - indexed for MEDLINE]
4.

Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.

Kuzhan A, Adli M, Eryigit Alkis H, Caglayan D.

J BUON. 2013 Jul-Sep;18(3):619-22.

PMID:
24065473
[PubMed - indexed for MEDLINE]
5.

A long-term survival pattern for breast cancer treated in a single institution.

Gokce T, Karadogan I, Akcay C.

Indian J Cancer. 2011 Apr-Jun;48(2):187-93. doi: 10.4103/0019-509X.82884.

PMID:
21768664
[PubMed - indexed for MEDLINE]
Free Article
6.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
[PubMed - indexed for MEDLINE]
7.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059. Epub 2012 Dec 13.

PMID:
23240985
[PubMed - indexed for MEDLINE]
8.

Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.

Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.

Asian Pac J Cancer Prev. 2012;13(8):4119-23.

PMID:
23098527
[PubMed - indexed for MEDLINE]
Free Article
9.

Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.

Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F.

J Clin Oncol. 2008 Mar 10;26(8):1260-8. doi: 10.1200/JCO.2007.13.4338.

PMID:
18323549
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M.

Ann Oncol. 2013 Mar;24(3):661-8. doi: 10.1093/annonc/mds430. Epub 2012 Sep 28.

PMID:
23022996
[PubMed - indexed for MEDLINE]
Free Article
11.

Immunohistochemically defined subtypes and outcome of apocrine breast cancer.

Dellapasqua S, Maisonneuve P, Viale G, Pruneri G, Mazzarol G, Ghisini R, Mazza M, Iorfida M, Rotmensz N, Veronesi P, Luini A, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2013 Apr;13(2):95-102. doi: 10.1016/j.clbc.2012.11.004. Epub 2012 Dec 14.

PMID:
23245877
[PubMed - indexed for MEDLINE]
12.

Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.

Torrisi R, Bagnardi V, Rotmensz N, Scarano E, Iorfida M, Veronesi P, Luini A, Viale G, Santoro A, Colleoni M, Goldhirsch A.

Breast Cancer Res Treat. 2011 Apr;126(2):431-41. doi: 10.1007/s10549-010-1340-y. Epub 2011 Jan 8.

PMID:
21221766
[PubMed - indexed for MEDLINE]
13.

Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.

Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, Galimberti V, Veronesi P, Luini A, Pruneri G, Bottiglieri L, Mastropasqua MG, Goldhirsch A, Viale G, Colleoni M.

Clin Breast Cancer. 2013 Feb;13(1):31-9. doi: 10.1016/j.clbc.2012.09.002. Epub 2012 Oct 24.

PMID:
23098574
[PubMed - indexed for MEDLINE]
14.

Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.

Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D.

Oncology. 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19.

PMID:
23257904
[PubMed - indexed for MEDLINE]
15.

Expression of AIB1 protein as a prognostic factor in breast cancer.

Lee K, Lee A, Song BJ, Kang CS.

World J Surg Oncol. 2011 Oct 29;9:139. doi: 10.1186/1477-7819-9-139.

PMID:
22035181
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.

Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.

J BUON. 2012 Apr-Jun;17(2):277-83.

PMID:
22740206
[PubMed - indexed for MEDLINE]
17.

Male breast cancers behave differently in elderly patients.

Tural D, Selçukbiricik F, Aydoğan F, Beşe N, Yetmen O, Ilvan Ş, Büyükünal E, Serdengeçti S.

Jpn J Clin Oncol. 2013 Jan;43(1):22-7. doi: 10.1093/jjco/hys193. Epub 2012 Nov 15.

PMID:
23159765
[PubMed - indexed for MEDLINE]
Free Article
18.

Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.

Ishihara M, Mukai H, Nagai S, Onozawa M, Nihei K, Shimada T, Wada N.

Oncology. 2013;84(3):135-40. doi: 10.1159/000345321. Epub 2012 Dec 11.

PMID:
23235554
[PubMed - indexed for MEDLINE]
19.

Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.

Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI.

Cancer. 2005 Jun 1;103(11):2241-51.

PMID:
15844176
[PubMed - indexed for MEDLINE]
Free Article
20.

Female breast cancer status according to ER, PR and HER2 expression: a population based analysis.

Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M, Zappa M.

Pathol Oncol Res. 2011 Sep;17(3):753-8. doi: 10.1007/s12253-011-9381-z. Epub 2011 Apr 10.

PMID:
21479875
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk